MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 12-16-2023
Biohaven Pharmaceutical Holding Company Ltd. EBITDA per Share 2011-2025 | BHVN
Annual EBITDA per Share Biohaven Pharmaceutical Holding Company Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.5 | -10.8 | -9.87 | -1.17 | -3.86 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.17 | -10.8 | -7.25 |
Quarterly EBITDA per Share Biohaven Pharmaceutical Holding Company Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -4.08 | -0.7 | - | -2.14 | -2.64 | -3.72 | -2.84 | -2.66 | -2.67 | -2.67 | -2.58 | -1.73 | -4.4 | -1.23 | -1.17 | -1.37 | -0.98 | -2.27 | -0.79 | -1.1 | -0.97 | -1.11 | -1.75 | -2.14 | -0.55 | -0.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.25 | -4.4 | -1.94 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-0.46 | $ 4.76 | -0.73 % | $ 790 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-1.83 | $ 3.01 | -1.15 % | $ 233 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.72 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-44.1 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
0.34 | $ 1.16 | -0.85 % | $ 6.33 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
0.15 | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-8.25 | $ 209.37 | -1.62 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-87.8 | $ 0.52 | -44.08 % | $ 144 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-1.68 | $ 3.29 | 6.3 % | $ 7.92 B |  Australia |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-12.1 | $ 1.16 | -8.66 % | $ 1.71 M | USA |
 |
Athersys
ATHX
|
-0.382 | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-8.71 | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-5.25 | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
0.24 | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
-1.38 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-0.11 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
0.38 | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
62.6 | $ 94.21 | -0.86 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
4.82 | $ 27.0 | 0.7 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-0.29 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 0.22 | 24.23 % | $ 479 M |  Israel |
 |
Anika Therapeutics
ANIK
|
-5.54 | $ 9.49 | 0.11 % | $ 139 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-0.87 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-1.29 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-1.97 | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-10.2 | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-1.56 | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-1.56 | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
1.41 | $ 583.31 | -1.33 % | $ 44.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-0.39 | $ 2.47 | -2.37 % | $ 15.5 M | USA |
 |
AstraZeneca PLC
AZN
|
0.74 | $ 92.76 | 0.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-188 | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
-1 | $ 12.37 | - | $ 814 M | USA |
 |
Brickell Biotech
BBI
|
-1.17 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
1.11 | $ 9.03 | 0.28 % | $ 1.48 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-2.98 K | $ 26.13 | -2.63 % | $ 1.68 M | USA |
 |
Biogen
BIIB
|
4.62 | $ 176.07 | -0.15 % | $ 25.6 B | USA |
 |
Cellectar Biosciences
CLRB
|
-3.17 | $ 2.55 | -7.47 % | $ 31.2 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-2.73 | - | - | $ 7.29 B | USA |